Cx3cr1

Tamoxifen (non-pharmaceutical grade) was purchased from Sigma-Aldrich (St Louis, MO). Giemsa cytological stain was purchased from Sigma-Aldrich. Antibodies used for in situ hybridization, immunohistochemical and flow cytometric analysis were: tgfb1 (Cat # 407751, Advanced Cell Diagnostics, ACD); RFP (Cat # ab62341; 1:1000, Abcam, Cambridge, MA); Arg1 (Cat # ab91279; 1:1500, Abcam); iNOS (Cat # ab15323; 1:200, Abcam); CD64 (Cat # bs-3511R; 1:250, Bioss Antibodies, Woburn, MA); CCR2 (Cat # EPR20844; 1:400, Abcam); phospho-SMAD2/3 (Cat # PA5-37636; 1.500, Invitrogen CX₃CR1 (Cat # bs-1728R; Bioss Antibodies); CD64 (Cat # bs-3511R; Bioss Antibodies); CD125/IL-5RA (Cat # bs-2601R, Bioss Antibodies); C1q (Cat # A0136; 1:500, Dako/Agilent Technologies, Santa Clara, CA); CD16/32 (clone 93; eBiosciences, San Diego, CA), CD11b (clone # M1/70; eFluo450, eBiosciences); Fixable Viability dye (Cat # 65-0865-14; eFluo780, eBiosciences); SigF (clone S17007L; PE-CF594, BD Biosciences, San Jose, CA); CD45 (clone 30-F11; PerCP5.5, Biolegend, San Diego, CA); CD11c (clone # N418; BV705, Biolegend); Ly6G (clone # 1A8; AF700, Biolegend); Ly6C (clone HK1.4, BV510, Biolegend); CD64 (clone X54-5/7.1; PE/Cy7, Biolegend); CD43 (clone # S11; PE, Biolegend); CD3 (clone # 17A2; BUV395, Biolegend). All other reagents were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA), or Sigma-Aldrich.

The anti-F4/80 antibody was purchased from Bio-Rad (Hercules, CA, USA). The anti-iNOS antibody was purchased from BD Transduction Laboratories (San Jose, CA, USA), Thermo Scientific (Fremont, CA, USA) or Abcam (Cambridge Science Park, Cambridge, UK). CX3CR1 was obtained from Bioss (Woburn, Massachusetts, USA). CD68 was obtained from Abcam and CD206 from Bioss, BIO-RAD (Hercules, CA, California) or R&D Systems (Minneapolis, MN, USA). Antibodies against phospho-STAT1, STAT1, phospho-STAT3, STAT3 and β-actin were purchased from Cell Signaling Technology (Danvers, MA, USA).